Foundry Partners LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 17.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 805,705 shares of the biopharmaceutical company’s stock after buying an additional 116,797 shares during the period. Pfizer accounts for 1.6% of Foundry Partners LLC’s investment portfolio, making the stock its largest position. Foundry Partners LLC’s holdings in Pfizer were worth $28,369,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Ronna Sue Cohen boosted its position in shares of Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 35 shares during the period. Forte Capital LLC ADV boosted its position in shares of Pfizer by 0.4% in the first quarter. Forte Capital LLC ADV now owns 8,589 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 36 shares during the period. Naples Global Advisors LLC boosted its position in shares of Pfizer by 0.4% in the second quarter. Naples Global Advisors LLC now owns 24,327 shares of the biopharmaceutical company’s stock valued at $857,000 after buying an additional 85 shares during the period. Capital Asset Advisory Services LLC boosted its position in shares of Pfizer by 0.5% in the second quarter. Capital Asset Advisory Services LLC now owns 21,259 shares of the biopharmaceutical company’s stock valued at $749,000 after buying an additional 100 shares during the period. Finally, Triangle Securities Wealth Management boosted its position in shares of Pfizer by 0.5% in the second quarter. Triangle Securities Wealth Management now owns 18,947 shares of the biopharmaceutical company’s stock valued at $667,000 after buying an additional 102 shares during the period. Institutional investors and hedge funds own 69.66% of the company’s stock.

Pfizer Inc. (NYSE:PFE) traded down 0.59% during mid-day trading on Friday, reaching $33.94. The company had a trading volume of 25,615,509 shares. The company has a market capitalization of $205.87 billion, a PE ratio of 30.09 and a beta of 0.87. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39. The firm has a 50-day moving average of $35.23 and a 200 day moving average of $33.72.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. During the same quarter in the prior year, the company earned $0.56 earnings per share. Pfizer’s revenue was up 10.9% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 1st. Shareholders of record on Friday, August 5th were issued a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 3.54%. The ex-dividend date was Wednesday, August 3rd. Pfizer’s dividend payout ratio is 95.24%.

Several brokerages have weighed in on PFE. Argus restated a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research note on Sunday, August 28th. Jefferies Group restated a “buy” rating and set a $42.00 price objective (up from $41.00) on shares of Pfizer in a research note on Tuesday, June 14th. Vetr cut Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price objective on the stock. in a research note on Tuesday, June 28th. Citigroup Inc. restated a “neutral” rating and set a $37.00 price objective on shares of Pfizer in a research note on Wednesday, August 3rd. Finally, Barclays PLC restated an “equal weight” rating and set a $34.00 price objective on shares of Pfizer in a research note on Tuesday, August 2nd. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $38.78.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.